Mismatch repair and drug responses in cancer

Drug Resistance Updates

Volumn 2, Issue 5, 1999, Pages 295-306

  Sedwick, W David ^a   Markowitz, Sanford D ^a   Veigl, Martina L ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 9 [3 (2 CHLOROETHYL)AMINOPROPYLAMINO] 2 METHOXYACRIDINE; ACRIDINE DERIVATIVE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; APHIDICOLON; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHYLNITROSOUREA; NITROSOUREA DERIVATIVE; TEMOZOLOMIDE; TIOGUANINE; UNCLASSIFIED DRUG;

BASE MISPAIRING; CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; COLON CANCER; CYTOTOXICITY; DNA REPAIR; DRUG RESPONSE; ENDOMETRIUM CANCER; FRAMESHIFT MUTATION; GENETIC DISORDER; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; REVIEW; STOMACH CANCER;

EID: 0033208509     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0099     Document Type: Article

References (111)

1. Modrich P., Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem. 65:1996;101-133.
2. Eshleman J. R., Lang E. Z., Bowerfind G. K. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene. 10:1995;33-37.
3. Eshleman J. R., Markowitz S. D. Microsatellite instability in inherited and sporadic neoplasms. Curr Opinion Oncol. 7:1995;83-89.
4. Bhattacharyya N. P., Skandalis A., Ganesh A. Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci USA. 91:1994;6319-6323.
5. Loeb L. A., Springgate C. F., Battula N. Errors in DNA replication as a basis of malignant changes. Cancer Res. 34:1974;2311-2321.
6. Nowell P. C. The clonal evolution of tumor cell populations. Science. 194:1976;23-28.
7. Fishel R., Lescoe M. K., Rao M. R. The human mutator gene homolog MSH 2 and its association with hereditary nonpolyposis colon cancer. Cell. 75:1993;1027-1038.
8. Parsons R., Li G. M., Longley M. J. Hypermutability and mismatch repair deficiency in RER + tumor cells. Cell. 75:1993;1227-1236.
9. Leach F. S., Nicolaides N. C., Papadopoulos N. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 75:1993;1215-1225.
10. Perucho M. Cancer of the microsatellite mutator phenotype. Biol Chem. 377:1996;675-684.
11. Eshleman J. R., Markowitz S. D. Mismatch repair defects in human carcinogenesis. Human Molecular Genetics. 5:1996;1489-1494.
12. Goldmacher V. S., Cuzick R. A. Jr, Thilly W. G. Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N-methyl-N'- nitro-N-nitrosoguanidine. J Biol Chem. 261:1986;12462-12471.
13. Friedman H. S., McLendon R. E., Kerby T. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 16:1998;3851-3857.
14. Thibodeau S. N., Bren G., Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 260:1993;816-819.
15. Ionov Y., Peinado M. A., Malkhosyan S. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 363:1993;558-561.
16. Kim H., Jen J., Vogelstein B. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Amer J Path. 145:1994;148-156.
17. Lynch H. T., Lanspa S., Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history, and cancer control, Part I. Cancer Genet Cytogenet. 53:1991;143-160.
18. Liu B., Nicolaides N. C., Markowitz S. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nature Genetics. 9:1995;48-55.
19. Veigl M. L., Kasturi L., Olechnowicz J. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA. 95:1998;8698-8702.
20. Herman J. G., Umar A., Polyak K. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 95:1998;6870-6875.
21. Deng G., Chen A., Hong J. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 59:1999;2029-2033.
22. Lynch H. T., Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer. 78:1996;1149-1167.
23. Marra G., Boland C. R. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst. 87:1995;1114-1125.
24. Kane M. F., Loda M., Gaida G. M. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57:1997;808-811.
25. Aaltonen L. A., Peltomaki P., Mecklin J. P. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res. 54:1994;1645-1648.
26. Loeb L. A. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res. 54:1994;5059-5063.
27. Streisinger G., Owen J. Mechanisms of spontaneous and induced frameshift mutation in bacteriophage T4. Genetics. 109:1985;633-659.
28. Umar A., Kunkel T. A. DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Eur J Biochem. 238:1996;297-307.
29. Eshleman J. R., Markowitz S. D., Donover P. S. Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability. Oncogene. 12:1996;1425-1432.
30. Parsons R., Myeroff L. L., Liu B. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. 55:1995;5548-5550.
31. Radman M., Matic I., Halliday J. A. Editing DNA replication and recombination by mismatch repair: from bacterial genetics to mechanisms of predisposition to cancer in humans. Phil Trans R Soc Lond B Biol Sci. 347:1995;97-103.
32. de Wind N., Dekker M., Berns A. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell. 82:1995;321-330.
33. Davis T. W., Wilson-Van P. C., Meyers M. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res. 58:1998;767-778.
34. Hawn M. T., Umar A., Carethers J. M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 55:1995;3721-3725.
35. Mellon I., Rajpal D. K., Koi M. Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science. 272:1996;557-560.
36. Mellon I., Champe G. N. Products of DNA mismatch repair genes mutS and mutL are required for transcription-coupled nucleotide-excision repair of the lactose operon in Escherichia coli. Proc Natl Acad Sci USA. 93:1996;1292-1297.
37. Leadon S. A., Avrutskaya A. V. Differential involvement of the human mismatch repair proteins, hMLH1 and hMSH2, in transcription-coupled repair. Cancer Res. 57:1997;3784-3791.
38. Bertrand P., Tishkoff D. X., Filosi N. Physical interaction between components of DNA mismatch repair and nucleotide excision repair. Proc Natl Acad Sci USA. 95:1998;14278-14283.
39. Dunlop M. G., Farrington S. M., Carothers A. D. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 6:1997;105-110.
40. Lengauer C., Kinzler K. W., Vogelstein B. Genetic instability in colorectal cancers. Nature. 386:1997;623-627.
41. Jackson A. L., Newcomb T. G., Loeb L. A. Origin of multiple mutations in human cancers. Drug Metab Rev. 30:1998;285-304.
42. Jackson A. L., Loeb L. A. The mutation rate and cancer. Genetics. 148:1998;1483-1490.
43. Loeb L. A. Cancer cells exhibit a mutator phenotype. Adv Cancer Res. 72:1998;25-56.
44. Jiricny J. Mismatch repair and cancer. Cancer Surveys. 28:1996;47-68.
45. Dunlop M. G. Mutator genes and mosaicism in colorectal cancer. Curr Opin Genet Dev. 6:1996;76-81.
46. Markowitz S. D. DNA repair defects inactivate tumor suppressor genes and induce hereditary and sporadic colon cancers. Amer Clin Oncol. 1999;56-62.
47. Yu Z., Chem J., Ford B. N. Human DNA repair systems: An overview. Environ Mol Mutagen. 33:1999;3-20.
48. Macpherson P., Humbert O., Karran P. Frameshift mismatch recognition by the human MutS alpha complex. Mutat Res. 408:1998;55-66.
49. Umar A., Risinger J. I., Glaab W. E. Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics. 148:1998;1637-1646.
50. Genschel J., Littman S. J., Drummond J. T. Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha. J Biol Chem. 273:1998;19895-19901.
51. Akiyama Y., Sato H., Yamada T. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res. 57:1997;3920-3923.
52. Marra G., Iaccarino I., Lettieri T. Mismatch repair deficiency associated with overexpression of the MSH3 gene. Proc Natl Acad Sci USA. 95:1998;8568-8573.
53. Drummond J. T., Genschel J., Wolf E. DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSalpha/hMutSbeta ratio and reduces the efficiency of base-base mismatch repair. Proc Natl Acad Sci USA. 94:1997;10144-10149.
54. Akiyama Y., Tsubouchi N., Yuasa Y. Frequent somatic mutations of hMSH3 with reference to microsatellite instability in hereditary nonpolyposis colorectal cancers. Biochem Biophys Res Commun. 236:1997;248-252.
55. Yamamoto H., Sawai H., Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 57:1997;4420-4426.
56. Percesepe A., Kristo P., Aaltonen L. A. Mismatch repair genes and mononucleotide tracts as mutation targets in colorectal tumors with different degrees of microsatellite instability. Oncogene. 17:1998;157-163.
57. Drummond J. T., Anthoney A., Brown R. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem. 271:1996;19645-19648.
58. Bertario L. Survival comparison between sporadic, familial polyposis and nonpolyposis colon cancer. Clin Oncol Alert. 14:1999;25-32.
59. Sankila R., Aaltonen L. A., Jarvinen H. J. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology. 110:1996;682-687.
60. Bocker T., Ruschoff J., Fishel R. Molecular diagnostics of cancer predisposition: hereditary non-polyposis colorectal carcinoma and mismatch repair defects. Biochim Biophys Acta. 1423:1999;1-10.
61. Eshleman J. R., Casey G., Kochera M. E. Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53. Oncogene. 17:1998;719-725.
62. Friedman H. S., Johnson S. P., Dong Q. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res. 57:1997;2933-2936.
63. Liu L., Markowitz S., Gerson S. L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res. 56:1996;5375-5379.
64. Fink D., Nebel S., Aebi S. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56:1996;4881-4886.
65. Aebi S., Kurdi-Haidar B., Gordon R. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56:1996;3087-3090.
66. Brown R., Hirst G. L., Gallagher W. M. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 15:1997;45-52.
67. Claij N., Te Riele H. Microsatellite instability in human cancer: a prognostic marker for chemotherapy? Exp Cell Res. 246:1999;1-10.
68. DeWeese T. L., Shipman J. M., Larrier N. A. Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. Proc Natl Acad Sci USA. 95:1998;11915-11920.
69. Fritzell J. A., Narayanan L., Baker S. M. Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res. 57:1997;5143-5147.
70. Boland C. R., Thibodeau S. N., Hamilton S. R. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58:1998;5248-5257.
71. Moreland N. J., Illand M., Kim Y. T. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res. 59:1999;2102-2106.
72. Carethers J. M., Chauhan D. P., Fink D. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 117:1999;123-131.
73. Glaab W. E., Risinger J. I., Umar A. Resistance to 6-thioguanine in mismatch repair-deficient human cancer cell lines correlates with an increase in induced mutations at the HPRT locus. Carcinogenesis. 19:1998;1931-1937.
74. Berry S. E., Garces C., Hwang H. S. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells. Cancer Res. 59:1999;1840-1845.
75. Chen, W. D. Eshleman, J. R. Aminoshariae, M. R. Vulnerability of mismatch repair deficient colon cancers to killing and to mutational promotion by treatment with a frameshift-inducing agent, ICR-191. J Natl Cancer Inst, in press.
76. Hernandez L., Cholody W. M., Hudson E. A. Mechanism of action of bisimidazoacridones, new drugs with potent, selective activity against colon cancer. Cancer Res. 55:1995;2338-2345.
77. Carethers J. M., Hawn M. T., Chauhan D. P. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine. J Clin Invest. 98:1996;199-206.
78. Markowitz S., Wang J., Myeroff L. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
79. Kat A., Thilly W. G., Fang W. H. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA. 90:1993;6424-6428.
80. Toft N. J., Winton D. J., Kelly J. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci USA. 96:1999;3911-3915.
81. Wedge S. R., Porteous J. K., Newlands E. S. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer. 74:1996;1030-1036.
82. D'Atri S., Tentori L., Lacal P. M. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol. 54:1998;334-341.
83. Glaab W. E., Tindall K. R., Skopek T. R. Specificity of mutations induced by methyl methanesulfonate in mismatch repair-deficient human cancer cell lines. Mutat Res. 427:1999;67-78.
84. Glaab W. E., Risinger J. I., Umar A. Cellular resistance and hypermutability in mismatch repair-deficient human cancer cell lines following treatment with methyl methanesulfonate. Mutat Res. 398:1998;197-207.
85. Waters T. R., Swann P. F. Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochem. 36:1997;2501-2506.
86. Reitmair A. H., Risley R., Bristow R. G. Mutator phenotype in Msh2-deficient murine embryonic fibroblasts. Cancer Res. 57:1997;3765-3771.
87. Risinger J. I., Barrett J. C., Watson P. Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer. 77:1996;1836-1843.
88. Fink D., Nebel S., Norris P. S. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer. 77:1998;741-746.
89. Mao E. F., Lane L., Lee J. Proliferation of mutators in a cell population. J Bacter. 179:1997;417-422.
90. LeClerc J. E., Payne W. L., Kupchella E. Detection of mutator subpopulations in Salmonella typhimurium LT2 by reversion of his alleles. Mutat Res. 400:1998;89-97.
91. Dosch J., Christmann M., Kaina B. Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. Carcinogenesis. 19:1998;567-573.
92. Anderson R. D., Veigl M. L., Baxter J. Excision repair reduces doxorubicin-induced genotoxicity. Mutat Res. 294:1993;215-222.
93. Kolodner R. D., Marsischky G. T. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 9:1999;89-96.
94. Hoffmann J. S., Pillaire M. J., Lesca C. Fork-like DNA templates support bypass replication of lesions that block DNA synthesis on single-stranded templates. Proc Natl Acad Sci USA. 93:1996;13766-13769.
95. Sessa C., Zucchetti M., Davoli E. Phase I and clinical pharmacological evaluation of aphidicolin glycinate. J Natl Cancer Inst. 83:1991;1160-1164.
96. Durant S. T., Morris M. M., Illand M. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr Biol. 9:1999;51-54.
97. Esteller M., Levine R., Baylin S. B. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene. 17:1998;2413-2417.
98. Strathdee G., MacKean M. J., Illand M. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 18:1999;2335-2341.
99. Snyder R. D., Lachmann P. J. Differential effects of 5-azacytidine and 5-azadeoxycytidine on cytotoxicity, DNA-strand breaking and repair of X-ray-induced DNA damage in HeLa cells. Mutat Res. 226:1989;185-190.
100. Jones P. A., Taylor S. M. Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells. Nucleic Acid Res. 9:1981;2933-2947.
101. Juttermann R., Li E., Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA. 91:1994;11797-11801.
102. Bhattacharya S. K., Ramchandani S., Cervoni N. A mammalian protein with specific demethylase activity for mCpG DNA. Nature. 397:1999;579-583.
103. Ramchandani S., Bhattacharya S. K., Cervoni N. DNA methylation is a reversible biological signal. Proc Natl Acad Sci USA. 96:1999;6107-6112.
104. Cholody W. M., Hernandez L., Hassner L. Bisimidazoacridones and related compounds: new antineoplastic agents with high selectivity against colon tumors. J Med Chem. 38:1995;3043-3052.
105. Markowitz S. D., Roberts A. B. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 7:1996;93-102.
106. Simms L. A., Zou T. T., Young J. Apparent protection from instability of repeat sequences in cancer-related genes in replication error positive gastrointestinal cancers. Oncogene. 14:1997;2613-2618.
107. Bicknell D. C., Kaklamanis L., Hampson R. Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol. 6:1996;1695-1697.
108. Riggins G. J., Thiagalingam S., Rozenblum E. Mad-related genes in the human. Nat Genet. 13:1996;347-349.
109. Jirtle R. L. Genomic imprinting and cancer. Exp Cell Res. 248:1999;18-24.
110. Narayanan L., Fritzell J. A., Baker S. M. Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2. Proc Natl Acad Sci USA. 94:1997;3122-3127.
111. Loeb L. A. Transient expression of a mutator phenotype in cancer cells (comment). Science. 277:1997;1449-1450.